Cellectar Biosciences Company Profile (NASDAQ:CLRB)

About Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences logoCellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLRB
  • CUSIP: N/A
  • Web: www.cellectar.com
Capitalization:
  • Market Cap: $21.69 million
  • Outstanding Shares: 13,462,000
Average Prices:
  • 50 Day Moving Avg: $1.97
  • 200 Day Moving Avg: $1.86
  • 52 Week Range: $1.06 - $4.58
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.90
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.22 per share
  • Price / Book: 1.39
Profitability:
  • EBIDTA: ($9,090,000.00)
  • Return on Equity: -48.85%
  • Return on Assets: -31.41%
Debt:
  • Current Ratio: 4.32%
  • Quick Ratio: 4.32%
Misc:
  • Average Volume: 337,219 shs.
  • Beta: 0.58
  • Short Ratio: 3.49
 

Frequently Asked Questions for Cellectar Biosciences (NASDAQ:CLRB)

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) released its earnings results on Thursday, May, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.01. View Cellectar Biosciences' Earnings History.

Where is Cellectar Biosciences' stock going? Where will Cellectar Biosciences' stock price be in 2017?

3 analysts have issued 1 year target prices for Cellectar Biosciences' shares. Their predictions range from $2.70 to $2.70. On average, they anticipate Cellectar Biosciences' share price to reach $2.70 in the next year. View Analyst Ratings for Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

How do I buy Cellectar Biosciences stock?

Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cellectar Biosciences stock cost?

One share of Cellectar Biosciences stock can currently be purchased for approximately $1.69.

Analyst Ratings

Consensus Ratings for Cellectar Biosciences (NASDAQ:CLRB) (?)
Ratings Breakdown: 1 Sell Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $2.70 (59.76% upside)

Analysts' Ratings History for Cellectar Biosciences (NASDAQ:CLRB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017ValuEngineDowngradeSell -> Strong SellLowView Rating Details
12/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$2.70N/AView Rating Details
12/21/2016Langenberg & CompanyInitiated CoverageBuy$2.70N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Cellectar Biosciences (NASDAQ:CLRB)
Earnings by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
Earnings History by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.23)($0.24)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.23)($0.35)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.20)($0.43)ViewN/AView Earnings Details
8/11/2016Q2 2016($0.40)($0.49)ViewN/AView Earnings Details
11/12/2015Q315($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.30)ViewListenView Earnings Details
5/21/2015Q115($0.30)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)
Current Year EPS Consensus Estimate: $-0.95 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS

Dividends

Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cellectar Biosciences (NASDAQ:CLRB)
Insider Ownership Percentage: 15.45%
Institutional Ownership Percentage: 1.25%
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016John NeisDirectorBuy333,333$1.49$496,666.17View SEC Filing  
10/31/2016Richard HertzbergInsiderSell21,000$2.03$42,630.00View SEC Filing  
4/20/2016James V CarusoCEOBuy46,948$2.12$99,529.76View SEC Filing  
4/20/2016Paul L BernsDirectorBuy117,371$2.12$248,826.52View SEC Filing  
12/31/2015Awm Investment Company, Inc.Major ShareholderSell100,000$0.69$69,000.00View SEC Filing  
12/29/2015Awm Investment Company, Inc.Major ShareholderSell82,847$0.69$57,164.43View SEC Filing  
12/28/2015Awm Investment Company, Inc.Major ShareholderSell367,966$0.73$268,615.18View SEC Filing  
12/22/2015Awm Investment Company, Inc.Major ShareholderSell7,938$0.90$7,144.20View SEC Filing  
12/21/2015Awm Investment Company, Inc.Major ShareholderSell27,621$0.92$25,411.32View SEC Filing  
12/17/2015Awm Investment Company, Inc.Major ShareholderSell71,225$0.87$61,965.75View SEC Filing  
12/15/2015Awm Investment Company, Inc.Major ShareholderSell44,965$0.82$36,871.30View SEC Filing  
12/4/2015Awm Investment Company, Inc.Major ShareholderSell50,950$1.06$54,007.00View SEC Filing  
11/24/2015Awm Investment Company, Inc.Major ShareholderSell173,802$1.24$215,514.48View SEC Filing  
11/24/2015James V CarusoCEOBuy1,000$1.30$1,300.00View SEC Filing  
11/20/2015Awm Investment Company, Inc.Major ShareholderSell96,806$1.17$113,263.02View SEC Filing  
11/20/2015James V CarusoCEOBuy1,000$1.16$1,160.00View SEC Filing  
11/19/2015James V. CarusoCEOBuy4,000$1.45$5,800.00View SEC Filing  
10/23/2015Awm Investment Company, Inc.Major ShareholderSell8,866$2.00$17,732.00View SEC Filing  
10/6/2015Awm Investment Company, Inc.Major ShareholderSell2,554$2.00$5,108.00View SEC Filing  
10/5/2015Awm Investment Company, Inc.Major ShareholderSell7,500$2.04$15,300.00View SEC Filing  
10/1/2015Awm Investment Company, Inc.Major ShareholderSell27,940$2.05$57,277.00View SEC Filing  
9/29/2015Awm Investment Company, Inc.Major ShareholderSell24,801$2.36$58,530.36View SEC Filing  
8/20/2014John NeisDirectorBuy268,711$3.75$1,007,666.25View SEC Filing  
8/20/2014Simon PedderCEOBuy13,300$3.75$49,875.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cellectar Biosciences (NASDAQ:CLRB)
Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)
Source:
DateHeadline
americanbankingnews.com logoCellectar Biosciences Inc (CLRB) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM
globenewswire.com logoThree Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 4:16 PM
finance.yahoo.com logoThree Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings
finance.yahoo.com - May 18 at 11:10 AM
reuters.com logoBRIEF-Cellectar Biosciences Q1 loss per share $0.24
www.reuters.com - May 12 at 9:56 PM
finance.yahoo.com logoEdited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:53 PM
americanbankingnews.com logoCellectar Biosciences Inc (CLRB) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 2:02 PM
finance.yahoo.com logoCellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - May 11 at 4:58 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences - PR Newswire (press release)
www.prnewswire.com - May 9 at 8:12 AM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and ... - Yahoo Finance
finance.yahoo.com - May 4 at 8:24 AM
americanbankingnews.com logoCellectar Biosciences (CLRB) Receives Media Sentiment Rating of 0.46
www.americanbankingnews.com - May 3 at 4:18 PM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance
finance.yahoo.com - May 2 at 4:22 PM
americanbankingnews.com logoCellectar Biosciences (CLRB) Getting Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 11:38 PM
finance.yahoo.com logoCellectar's Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical ... - Yahoo Finance
finance.yahoo.com - April 27 at 9:53 PM
streetinsider.com logoCellectar Biosciences (CLRB) Says CLR 131 and CLR 125 Demonstrate Increased Survival Benefit Using Multiple Doses in Preclinical Studies
www.streetinsider.com - April 27 at 9:56 AM
finance.yahoo.com logoCellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
finance.yahoo.com - April 27 at 9:56 AM
streetinsider.com logoCellectar Biosciences (CLRB) Announces Patents for PDC Optical Agents in Detection of Multiple Cancers
www.streetinsider.com - April 25 at 12:11 PM
finance.yahoo.com logoCellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers
finance.yahoo.com - April 25 at 12:11 PM
americanbankingnews.com logoCellectar Biosciences (CLRB) Earning Very Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 22 at 9:55 AM
globenewswire.com logoUPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief ... - GlobeNewswire (press release)
globenewswire.com - April 21 at 4:25 PM
finance.yahoo.com logoUPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
finance.yahoo.com - April 21 at 4:25 PM
streetinsider.com logoCellectar Biosciences (CLRB) Receives Japanese Patent for CLR 131 and CLR 125 - StreetInsider.com
www.streetinsider.com - April 19 at 9:22 PM
americanbankingnews.com logoCellectar Biosciences (CLRB) Receiving Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 19 at 7:40 AM
finance.yahoo.com logoCellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells
finance.yahoo.com - April 18 at 12:21 PM
streetinsider.com logoCellectar Biosciences (CLRB) Names John Friend, MD as CMO - StreetInsider.com
www.streetinsider.com - April 13 at 4:24 PM
americanbankingnews.com logoCellectar Biosciences (CLRB) Earning Very Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 13 at 8:27 AM
finance.yahoo.com logoCellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
finance.yahoo.com - April 12 at 10:43 AM
finance.yahoo.com logoCellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
finance.yahoo.com - April 10 at 4:15 PM
streetinsider.com logoCellectar Biosciences (CLRB) Initiates NCI-Supported Phase II Trial of CLR 131 in MM and Other Blood Cancers
www.streetinsider.com - March 30 at 4:47 PM
us.rd.yahoo.com logoAfter Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
us.rd.yahoo.com - March 30 at 4:47 PM
streetinsider.com logoCellectar Biosciences (CLRB) Granted Patent for PET Imaging PDC
www.streetinsider.com - March 21 at 9:38 PM
us.rd.yahoo.com logoCELLECTAR BIOSCIENCES, INC. Financials
us.rd.yahoo.com - March 21 at 4:38 PM
us.rd.yahoo.com logoCellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC
us.rd.yahoo.com - March 21 at 11:40 AM
finance.yahoo.com logoEdited Transcript of CLRB earnings conference call or presentation 15-Mar-17 10:00pm GMT
finance.yahoo.com - March 16 at 5:42 PM
seekingalpha.com logoCellectar Biosciences' (CLRB) CEO James Caruso on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 2:54 AM
biz.yahoo.com logoCELLECTAR BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 15 at 4:46 PM
finance.yahoo.com logoCellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017
finance.yahoo.com - March 15 at 4:46 PM
streetinsider.com logoCellectar Biosciences (CLRB) Newly Issued Japanese Patent For PDC Optical Agents
www.streetinsider.com - March 15 at 6:41 AM
investopedia.com logoCellectar Biosciences Gets Japanese Patent (CLRB)
www.investopedia.com - March 14 at 4:13 PM
us.rd.yahoo.com logoCellectar Biosciences Secures Japanese Patent
us.rd.yahoo.com - March 14 at 4:13 PM
us.rd.yahoo.com logoNewly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio
us.rd.yahoo.com - March 14 at 12:49 PM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance
finance.yahoo.com - March 9 at 4:56 PM
us.rd.yahoo.com logoExpanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement
us.rd.yahoo.com - March 8 at 5:05 PM
finance.yahoo.com logoCellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free …
finance.yahoo.com - February 27 at 3:43 PM
us.rd.yahoo.com logoCellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months
us.rd.yahoo.com - February 27 at 3:43 PM
biz.yahoo.com logoCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 23 at 2:33 AM
us.rd.yahoo.com logoUpon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma
us.rd.yahoo.com - February 22 at 11:33 AM
finance.yahoo.com logoUPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 13 at 5:01 PM
finance.yahoo.com logoCellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma
finance.yahoo.com - February 13 at 5:01 PM
finance.yahoo.com logoCellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
finance.yahoo.com - February 9 at 4:44 PM
globenewswire.com logoCellectar Biosciences to Present at 2017 BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 7 at 5:25 PM

Social

Chart

Cellectar Biosciences (CLRB) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff